You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

261 Results
Guidelines and Advice
Updated
Aug 2025
Guidelines and Advice
Status: Current
ID: GL 16-3
Version: 3
Mar 2022
Drug
Other Name(s): Vyloy®
Updated
Sep 2025
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Zolbetuximab - First-line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Sep 2025
Guidelines and Advice

Pages